Pfizer and BioNTech start late-stage study of lead Covid-19 shot

Pfizer and BioNTech said that they had selected a lead vaccine candidate from within a broader development programme and will proceed with a later-stage safety and efficacy trial of the experimental shot in a two-dose regimen
Pfizer and BioNTech SE said they’ve begun a later-stage trial for their top coronavirus vaccine candidate and set a goal of submitting it for regulatory review as soon as October — one of the most ambitious timelines to date.

 

The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc, which anno­unced earlier Monday that it had started its own large, final-stage trial of a shot based on similar technology.

 

Pfizer and BioNTech said that they had selected a lead vaccine candidate from within a broader development programme and will proceed with a later-stage safety and efficacy trial of the experimental shot in a two-dose regimen. The announcement came in anticipation of Pfizer reporting second-quarter earnings on Tuesday.

 

Governments around the world are now looking to lock up supplies of the still-experimental candidates.

 

Each has hopes of stabil­ising local economies and stopping spread of the virus that’s taken more than 650,000 lives globally. Last week, Pfizer and BioNTech clinc­hed a $2 billion deal to supply an initial 100 million doses of a vaccine to the US. That set a price ceiling of less than $20 per dose, which will likely impact how much others will charge.

           

 



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel